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Abstract: One and a half years into the pandemic, SARS-CoV-2 is still here to stay. Whilst rapid several effective COVID-19 vaccines
have been developed and are being rolled out, the critical questions remain whether vaccines provide widespread protection against
infection and reinfection, and what the duration of protection is. Community wide control cannot be obtained until almost everyone is
immune. Vaccine production must be ramped up to cover the world population. The price of herd immunity through natural infection is
high mortality in the elderly and morbidity in other age groups including children and Long-COVID. We must expect a new wave in the
coming winter. The severity will depend on the proportion of the population with immunity from natural infections or immunisation.
Therefore, control rests on a population wide immunisation including children, which may or may not need to be repeated if new SARSCoV-2 variants evolve that can escape immunity from either previous infections or immunisations. Preventing long term sequelae of
COVID-19 also remains a priority.
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1. Introduction
When COVID-19 pandemic was declared a global
emergency, in early 2020, the scientific and public
health communities hypothesized that SARS-CoV-2
transmission would eventually be brought under control
by herd immunity, conferred by natural infection, vaccine
development and rollout, or both [1]. Whilst rapid several
effective COVID-19 vaccines have been developed and
are being rolled out, the critical questions remain whether
vaccines provide widespread protection against infection
and reinfection, and what the duration of protection is [2].
One and a half years ago when the SARS-CoV-2
outbreak started in China, most experts expected a course
like pandemic influenza with seasonal transmission for
three to four months, followed by a pause over the summer
and a second wave next winter.
SARS-CoV-2 has proved very different with sustained
transmission during all seasons and epidemic waves have
only been brought under control by severe, country-wide
interventions to prevent transmission, strict movement

and travel restrictions, so called lock-downs associated
with implementation of infection control measures.
With massive rollout of COVID-19 vaccines, most highincome countries have protected the most vulnerable,
and are heading towards relaxing lockdown restrictions,
although low-income countries have not benefitted yet.
The inequalities in vaccine distribution and access need to
be addressed seriously if global COVID-19 control is to be
achieved.
2. Characteristics and implications of the pandemic
2.1. SARS-CoV-2 versus influenza
So why does SARS-CoV-2 behave different from pandemic
influenza? One hypothesis could be that we have all
been exposed to influenza throughout life by either
natural infections or immunisations, which has created
a population background immunity. In contrast, humans
had no background immunity against SARS-CoV-2 since
it is a novel zoonotic pathogen. Therefore, repeated waves
of SARS-CoV-2 coupled with worldwide immunisation
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campaigns are required to build herd immunity. The
trajectory of spread of novel viruses is variable, with
some novel viruses becoming less virulent with time or
disappearing altogether. For SARS-CoV-2 we do not know.
2.2. Transmissibility of SARS-CoV-2 – the basic
reproduction number, R0
Knowledge of the basic reproductive number R0 over time
is important for understanding the dynamics of SARSCoV-2 transmission. Most estimates indicate an R0 around
2.5 with a doubling time of around 5 days. Excretion of the
virus is at its peak when symptoms start which severely
reduces the effect of quarantining symptomatic people.
Besides, a proportion of infected people are asymptomatic
[3,4]. There remain several knowledge gaps regarding
how transmission of COVID-19 is ongoing in different
geographical settings across the world.
2.3. Herd immunity and immunisation of children
Herd immunity, defined as a “high proportion of immunity
in a population that prevents further transmission” has
proven elusive for SARS-CoV-2 transmission during
the first 18 months of the pandemic. With a R0 value
of approximately 2.5, transmission would need to be
reduced by more than 60% (1–1/R0) to reach a Re (basic
reproduction number after mitigation efforts) of less than
1. If the R0 is higher as it has been implicated with some
of the variant SARS-CoV-2 lineages, so called variants of
concern (VOC).1 A larger proportion of the population
needs to be immune. That means that we have to immunize
a high proportion of the population probably up towards
90%.
That will not be possible without immunizing children
perhaps down to the age of two years and perhaps in the
future a vaccine against SARS-CoV-2 will be included
in the childhood immunisation program [5]. Children
can also be severely ill from SARS-CoV-2. A study from
France [6] found that among patients younger than 18
years, the rates of intensive care unit (ICU) admission were
significantly higher for COVID-19 than for influenza.
The need for intensive care was highest in patients with
COVID-19 who were younger than 5 years, 2.3% for
COVID-19 versus 0.9% for influenza. Mortality was tentimes higher in children aged 11–17 years admitted to
hospital with COVID-19 than in patients in the same
age group admitted with influenza, 1.1% versus 0.1% [6].
COVID-19 is not an innocent infection in children and
adolescents.
VOCs might be able to evade infection or vaccineinduced neutralizing antibodies, thus lead to a growing
number of reinfections. One study demonstrated that
cross reactivity of SARS-CoV-2 specific T-cell mediated
immunity might protect against severe disease [7].

In addition, a recent study in Israel where a large
proportion of population have been vaccinated showed
that there is a cross protection of unvaccinated individuals,
hence a significant reduction in transmission rates [8]. The
duration of protection is not yet well known and further
studies are required.
Thus, a strategic plan to ensure a faster and widespread
immunization of the population including children is
needed.
2.4. Transmission of SARS-CoV-2 variants and future
modelling
An early modelling (May 2020) of different scenarios
predicted recurrent waves depending on acquired
population immunity and R0 [9]. The model did not
account for emergence of new variants or vaccines. A later
study predicted that “once the endemic phase is reached
and primary exposure is in childhood, CoV-2 may be no
more virulent than the common cold” [10]. However, this
presumptive benign nature of SARS-CoV-2 and especially
the VOCs can be questioned. Protective immunity against
VOCs either from infections with previous lineages or
vaccines are not known, but an influenza like situation
where acquired immunity is not fully protective can easily
be imagined.
Early studies have shown that PfizerBioNTech and
Moderna mRNA COVID-19 vaccines were highly
effective to prevent SARS-CoV-2 infection during the
period when the majority of infections are believed to
have been the original SARS-CoV-2 not yet being replaced
by the alpha variant [11–13]. High protective efficacy
(83.5% and 65.9%, respectively) was also reported for an
inactive virus vaccine CoronaVac [Sinovac Life Sciences
(Beijing, China)] in two different studies from Turkey and
Chile; considering the time periods of both studies, the
majority of infections in the studies are thought to have
been the original SARS-CoV-2 and the alpha variant,
respectively [14,15]. A more recent study that examined
virologic efficacy of three [Pfizer-BioNTech, Moderna, and
Janssen (Johnson & Johnson)] COVID-19 vaccines before
and during the predominance of SARS-CoV-2 B.1.617.2
(Delta) variant reported that the adjusted efficacy was
66% (95% CI = 26%–84%) during the Delta-predominant
period versus 91% (95% CI = 81%–96%) during the preDelta period. (16) We are not sure whether this loss of
efficacy is due to the low efficacy of the vaccine against
the delta variant or to the declining protective effect of
the vaccine within time. No study exists on the efficacy of
inactive coronavirus vaccines on VOCs.
In Table 1, we have attempted to compare what we
know about major VOCs and vaccine protective efficacy.

World Health Organization (2021). WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern [online]. Website
https://www.who.int/news/item/31-05-2021-who-announces-simple-easy-to-say-labels-for-sars-cov-2-variants-of-interest-and-concern [accessed 06
June 2021].
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Table 1. Approximate protective efficacy of major SARS-C0V-2 vaccines against the major antigenic variants, so called variants of
concern(VOC). 1
VOC new
Previous
Country first
nomen-clature nomen-clature identified

Protective efficacy
Pfizer/Biontech;
Moderna

Astra/Zeneca

Johnson&
Johnson

Novavax

Sinovac

a

B.1.1.1.7

United Kingdom

100%

75% (66%)

75%

90%

50.7%–83.5%

b

B.1.351

South Africa

75%

20%

60%

50%

Not known

g

P.1

Brazil

Not known

Not known

70%

Not known

Not known

d

B1.617.2

India

88%

60%–65%

Not known

80%

Not known

The numbers are approximate but illustrate that the
protective efficacy of the different vaccines is different and
more studies are needed especially monitoring COVID-19
in populations after infections and immunisations and
extensive sequencing of new infections become more and
more important as the virus evolves.
2.5. Vaccine supply
The World Health Organization (WHO) Strategic
Advisory Group of Experts on Immunization (SAGE)
released a document on September 14, 2020 to promote
equitable global access to safe and effective vaccines among
all countries, giving emphasis to low-and middle-income
countries.2 However, current vaccination rates range from
13% in India where the burden of the pandemic is huge and
the consequences are devastating, to 63% in Israel and only
39.4% of the global population received at least one dose.
The situation is far worse in low-income countries with
only 1.7% of people having received at least one dose.3 The
limited production capacity, shortage of raw materials and
consumables used in the production process coupled with
the purchase agreements signed by high-income countries
in advance have already hampered access to vaccines by
less developed and lower-income countries creating an
inequity between regions and populations similar to that
experienced in 2009 with the influenza vaccine [17–19].
Many countries do not seem to be likely to achieve massive
vaccination until the end of 2022, which creates a major
challenge in controlling the epidemic.
2.6. Long term sequelae “Long-COVID”
One recent study found that SARS-CoV-2 coursed
substantial immune activation in the central nervous

system with pronounced neuropathology [20]. Altered
brain T cell–microglial interactions were linked to
clinical measures of systemic inflammation and disturbed
hemostasis [21]. Recent data from the United Kingdom
shows that twelve weeks after acute COVID-19, 13.7%
continued to experience symptoms.4 Among people
suffering from Long-COVID 63.7% experienced some
limitation to their day-to-day activities and 18.8% reported
that their day-to-day activities had been limited a lot.4
The number of people with Long-COVID in a country
will thus depend on the proportion obtaining immunity
from natural infection compared to immunization. A
proportion of people with Long-COVID will seek medical
help and thus there will be a pressure on the health care
systems to investigate and help these patients. Probably
special Long-COVID outpatient clinics and rehabilitation
programs need to be developed and we do not know what
happens in the long term after twelve weeks. Therefore,
there will be an increased burden on health care systems
even months after the outbreak peaked.
2.7. The zoonotic connection
Modelling studies can give a certain prediction but
cannot predict the future. The outbreak in India was most
probably started by the mass gathering Hindu festival
Kumbh Mela and this illustrates how quickly the situation
can spin out of control and how public health precautions
need to continue for the foreseeable future.
The SARS-CoV-2 is a zoonosis probably arising
among farmed animals in China. The outbreak in mink
and the easy transmission between humans and mink was

World Health Organization (2021). WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination [online]. Website
https://apps.who.int/iris/bitstream/handle/10665/334299/WHO-2019-nCoV-SAGE_Framework-Allocation_and_prioritization-2020.1-eng.pdf?ua=1
[accessed 10 June 2021].
2

Our World in Data (2021). Coronavirus (COVID-19) Vaccinations [online]. Website https://ourworldindata.org/covid-vaccinations [accessed 10 June
2021].
3

Office for National Statistics (2021). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 4 June 2021. Statistical
Bulletin, Office for national Statistics, United Kingdom, 2 May 2021 [online]. Website https://www.ons.gov.uk/peoplepopulationandcommunity/
healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/4june2021
[accessed 10 June 2021].
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a warning [21,22]. We need to intensify surveillance of
SARS-CoV-2 and other corona virus in animals, especially
farmed animals living in cramped conditions and in
close contact to humans. There has been limited reports
of infections in dogs and felines but coronavirus may in
theory infect any mammal.
A recent study found that between May 2017 and
November 2019, 38 different animal species of which 31
were protected were sold at Wuhan markets [23]. It is a
real threat that SARS-CoV-2 may disappear into some
animal reservoir and reenter humans later depending on
the genetic evolution in that species and the population
immunity in human populations just as for influenza
[24]. Therefore, enhanced surveillance of farmed animals
especially in large, indoor facilities (pigs, poultry, cattle,
etc.) including sequencing to identify SARS-CoV-2
variants is urgently needed.

3. Conclusion
SARS-CoV-2 is here to stay. Community wide control
cannot be obtained until almost everyone is immune.
Vaccine production must be ramped up to cover the world
population.
The price of herd immunity through natural infection
is high mortality in the elderly and morbidity in other age
groups including children and Long-COVID.
We must expect a new wave in the coming winter.
The severity will depend on the proportion of the
population with immunity from natural infections or
immunisation. Therefore, control rests on a population
wide immunisation including children, which may or may
not need to be repeated if new SARS-CoV-2 variants evolve
that can escape immunity from either previous infections
or immunisations. Preventing long term sequelae of
COVID-19 also remains a priority.
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